Aktuella utlysningar, vecka 48, 2021
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Research grants – Swedish Match
These support research that increases knowledge about the physical, mental and social conditions of children and adolescents that affect their health and adjustment, or that in the elderly sheds light on various aspects of physical and mental changes, which are a consequence of aging. Grant is worth SEK 15,000 per month for two to four months.
Closing date: 31 December 2021
Grants for brain research – Märta Lundqvist Foundation
These support research at Swedish universities that is related to the field of the human brain. Priority is given to patient-centered and clinically focused research. Researchers at Swedish higher education institutions with a doctoral degree after 1 January 2017 can apply. The total budget is SEK 2.09 million.
Closing date: 13 January 2022
Utlysning av forskningsmedel – Försäkringskassan
Försäkringskassan utlyser forskningsmedel för projekt om socialförsäkringen och Försäkringskassans verksamhet. Årets utlysning är inriktat mot området psykisk ohälsa (psykiska sjukdomar och syndrom och psykiatriska tillstånd), särskilt i relation till aktivitets- och arbetsförmåga.
Closing date: 28 February 2022
Acute rheumatic fever biomarker project - Leducq Foundation
Leducq Foundation invites applications for its acute rheumatic fever biomarker project. This supports the identification of a biomarker for acute rheumatic fever that can serve as a basis for a test or panel of tests to accurately distinguish patients with acute rheumatic fever from individuals who do not have acute rheumatic fever.
Applicants may be based anywhere in then world. They must have relevant expertise in bacteriology, immunology, assay development, epidemiology or a related ﬁeld. The grant is worth USD 8 million for five years.
Closing date (Letter of intent): 21st January 2022
ERA PerMed invites applications for its joint transnational call on prevention in personalised medicine call. This supports research on prevention in personalised medicine. The aim is to develop tailor-made strategies for the prevention of disease and disease progression at three different levels:
•preventive measures decreasing the rate of incidence – primary prevention;
•early detection to increase the efficacy of a preventive therapy, even before symptoms are developed – secondary prevention;
•interventions preventing disease recurrence or improving patients’ care and quality of life – tertiary prevention.
Each proposal must address at least one of the following research areas: translating basic to clinical research and beyond; data and ICT; responsible and effective implementation in healthcare. Proposals may be submitted by those in academia, research institutes, the clinical or public health sector or the private sector. Each consortium must involve at least three partners from three different countries whose funding organisations participate to the call. The total budget is approximately €27 million.
Planned closing date (pre-proposal): 17th February 2022
Pezcoller/Marina Larcher Fogazzaro/EACR women in cancer research award - European Association for Cancer Research
The European Association for Cancer Research invites nominations for the Pezcoller/Marina Larcher Fogazzaro/EACR women in cancer research award. This recognises achievements by women in the field of cancer research. Self-nominations are not allowed. Nominees must have spent the majority of their research career in Europe and be employed by a research institute in Europe.
The award is worth €10,000. The winner also gives the Pezcoller-Marina Larcher Fogazzaro-EACR women in cancer research award lecture at the EACR congress.
Closing date: 10th January 2022
Eppendorf award for young European investigators - Eppendorf AG, and other funders
The Eppendorf AG, in partnership with the scientific journal Nature, invites applications for its award for young European investigators. This recognises contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.
European researchers, not older than 35 years, who hold a PhD or MD may apply. The award consists of €20,000 plus coverage of the prize winner’s work by Nature in print and online.
Closing date 16th January 2022
Federal Funding agencies
Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research: NIH
Celiac disease is an autoimmune disease that occurs in genetically susceptible individuals who develop an immune response to ingested gluten. This disease affects greater than 1% of the US population, and incidence appears to have been increasing over the last several decades. The only known treatment is life-long strict avoidance of all forms of wheat, rye, and barley.
Clinical manifestations are multifaceted and include gastrointestinal (ranging from severe malabsorption to subclinical damage of the gastrointestinal tract) as well as extraintestinal (e.g., skin) expressions of disease. The pathogenesis of celiac disease involves a combination of predisposing genes, gluten, and environmental factors. HLA-DQ2 and/or HLA-DQ8 haplotypes are the predominant predisposing genes, and dietary gluten is the major inciting factor in individuals with celiac disease.
While much is understood about the mechanism of disease, unmet needs in understanding celiac disease pathogenesis remain, including limited understanding of pathways of disease and tissue destruction, and what causes the loss of tolerance to a component of food.
The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Institutes of Health (NIH) of special interest in research on the etiology and pathogenesis of celiac disease, identification of therapeutic targets, and development of preventative or disease ameliorating therapies/strategies.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Deadline: April 22, 2022, September 22, 2022.
Funding Opportunity Announcement (FOA): RFA-CA-22-001.
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerateand/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
Deadline: April 22, 2022, September 22, 2022.
Funding Opportunity Announcement (FOA): RFA-CA-22-001.
Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-22-067, seeks shorter, higher-risk R21 grant applications.
Funding Opportunity Announcement (FOA): PAR-22-066 (R01); PAR-22-067 (R21).
Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed): NIH
The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community.
Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.
Deadline: June 10, 2022.
Funding Opportunity Announcement (FOA): RFA-RM-22-006.
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required: FDA
The purpose of this funding opportunity announcement (FOA) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
Deadline: February 15, 2022; February 13, 2024: by 11:59 PM Eastern Time.
Funding Opportunity Announcement (FOA): RFA-FD-22-001.
Research on Autism Spectrum Disorders (R01, R03, R21 Clinical Trial Optional): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA,PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.
Deadline: Standard dates apply, by 5:00 PM local time of applicant organization until March 6, 2024.
Funding Opportunity Announcement (FOA): PA-21-201 (R01); PA-21-199 (R03); PA-21-200 (R21).
NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed): NIH
This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.
Deadline: Standard dates apply, by 5:00 PM local time of applicant organization until May 8, 2022.
Funding Opportunity Announcement (FOA): PAR-19-260.
Neuroscience Investigator Awards & Stem Cell Investigator Awards- New York Stem Cell Foundation (NYSCF), US
Neuroscience Investigator Awards:
NYSCF is soliciting applications from early career investigators for awards in neuroscience. The goal of this initiative is to foster innovative, emerging scientists whose pioneering approaches have the potential to transform the field of neuroscience.
For the 2022 application cycle, applicants are invited to apply from all fields in neuroscience. NYSCF is committed to supporting a broad range of neuroscience research areas representative of the field, taking into account the immense progress and changes in the field in the last decade. To that end, NYSCF especially encourages applications from neuroscientists whose research areas may be under-supported by traditional funding mechanisms and/or underrepresented in the field as a whole (see examples on next page) or by previous recipients of the Awards.
Stem Cell Investigator Awards:
NYSCF is soliciting applications from early career investigators for awards to be used for exploring the basic biology and translational potential of stem cells. The aim of this initiative is to support highly innovative, emerging scientists whose pioneering approaches have the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease.
NYSCF is eager to support scientists who have just started their independent laboratories, and we strongly encourage applicants looking to secure their first major grant funding as an independent investigator. That being said, applicants will be evaluated first and foremost on scientific merit and the transformative potential of their research for the stem cell field.
Both career development award provides up to $1.5 million in flexible funding over 5 years.
Deadline: February 16, 2022, 5:00pm Eastern.
Research Award & Research Support Grant - Massage Therapy Foundation, US
The Massage Therapy Foundation now offers two types of research grants: Research Support Grants (up to $30,000 for one year) and Research Awards (over $30,000).
Massage Therapy Foundation research grants are awarded to individuals or teams conducting studies that promise to advance our understanding of specific therapeutic applications of massage, public perceptions of and attitudes toward massage therapy, and the role of massage therapy in health care delivery.
MTF research grants support high quality, independent research that contributes to the basic science of massage therapy application, including applied research investigating massage therapy as a health/mental health treatment and/or prevention modality. The research grant is available to investigators who have experience in the relevant field of research, and are presently associated with a university, independent research organization, or other institution qualified to act as Sponsoring Organization.
- MTF Research Support Grant: full proposal due February 1, 2022 at 11:59pm CST.
- MTF Research Award :
- pre-proposal (LOI) submission deadline: March 1, 2022 at 11:59pm CST,
- LOI Decision Notification: May 1, 2022,
- Invite-only full application deadline: August 1, 2022 at 11:59pm CST